GDC-8264

DRUG3 trials

Sponsors

Genentech Inc., Genentech, Inc.

Conditions

Acute Graft-versus-host DiseaseAcute Kidney InjuryPatients with moderate to high risk for cardiac surgery associated- acute kidney injury (CSA-AKI)

Phase 1

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

CompletedNCT05673876

Genentech, Inc.Acute Graft-versus-host Disease

Start: 2023-04-06End: 2024-01-15Updated: 2025-05-28

Phase 2

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

TerminatedNCT06602453

Genentech, Inc.Acute Kidney Injury

Start: 2025-01-17End: 2026-03-03Updated: 2026-03-16

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of GDC-8264 in preventing Cardiac Surgery-Associated Acute Kidney Injury and Major Adverse Kidney Events

RecruitingCTIS2024-513125-23-00

Genentech Inc.Patients with moderate to high risk for cardiac surgery associated- acute kidney injury (CSA-AKI)

Start: 2025-02-28Target: 175Updated: 2025-11-12